Skip to main content

Table 1 Patient, treatment, and disease characteristics

From: Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy

Characteristics

N (%) or median (range)

No. of patients

132

Age (years)

65.5 (41.7–84.1)

Sex

 

Male

75 (56.8)

Female

57 (43.2)

ECOG

 

0

50 (37.9)

1–2

82 (62.1)

Histology

 

Adenocarcinoma

131 (99.2)

Undifferentiated carcinoma

1 (0.8)

Location of primary tumor

 

Head

59 (44.7)

Other

73 (55.3)

Disease extent

 

Borderline resectable

41 (31.1)

Locally advanced

91 (69.9)

Baseline CA 19-9 (U/mL)

183.9 (1.0–7358.4)

Induction chemotherapy duration (months)

4 (1–18)

Induction chemotherapy regimen

 

mFFX

103 (78.0)

GnP

21 (15.8)

mFFX and GnP

5 (3.8)

mFFX plus other

1 (0.8)

GnP plus other

1 (0.8)

Other

1 (0.8)

SBRT dose and fractionation

 

33 Gy in 5 fractions

128 (97.0)

30 Gy 5 fractions

2 (1.4)

36 Gy in 5 fractions

1 (0.8)

30.5 Gy in 5 fractions

1 (0.8)

PTV (cm3)

132.0 (13.1–428.3)

Surgically Resected

90 (68.2)

Whipple procedure

54 (60.0)

Distal prancreatectomy

31 (34.4)

Total pancreatectomy

5 (5.6)

  1. ECOG Eastern Cooperative Oncology Group, CA 19-9, carbohydrate antigen 19-9, mFFX modified FOLFIRINOX, GnP gemcitabine/nab-paclitaxel, SBRT stereotactic body radiation therapy, PTV planning target volume, ALC absolute lymphocyte count